Aurora Private Wealth’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-3,513
Closed -$204K 160
2023
Q3
$204K Sell
3,513
-301
-8% -$18.4K 0.23% 122
2023
Q2
$244K Buy
3,814
+555
+17% +$37.2K 0.28% 103
2023
Q1
$226K Sell
3,259
-1,401
-30% -$98.8K 0.24% 126
2022
Q4
$335K Buy
4,660
+306
+7% +$23.1K 0.38% 78
2022
Q3
$310K Buy
4,354
+14
+0.3% +$1.02K 0.14% 111
2022
Q2
$334K Sell
4,340
-1,642
-27% -$125K 0.15% 106
2022
Q1
$437K Sell
5,982
-364
-6% -$24.4K 0.18% 104
2021
Q4
$396K Sell
6,346
-15,764
-71% -$925K 0.17% 106
2021
Q3
$1.31M Sell
22,110
-1,497
-6% -$98.6K 0.53% 35
2021
Q2
$1.58M Buy
23,607
+1,332
+6% +$86.9K 0.63% 32
2021
Q1
$1.41M Sell
22,275
-1,760
-7% -$110K 0.58% 28
2020
Q4
$1.49M Sell
24,035
-2,213
-8% -$136K 0.63% 22
2020
Q3
$1.58M Buy
26,248
+429
+2% +$25.8K 0.68% 22
2020
Q2
$1.52M Sell
25,819
-20,127
-44% -$1.2M 0.7% 24
2020
Q1
$2.56M Buy
45,946
+22,039
+92% +$1.35M 0.9% 20
2019
Q4
$1.53M Buy
+23,907
New +$1.37M 0.54% 33

Other funds holding BMY

Aurora Private Wealth's BMY Position: Q4 2023 in Review

Aurora Private Wealth sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 3,513 shares — an estimated $204K sold.

Aurora Private Wealth first reported a position in BMY in Q4 2019 and held it in 16 quarters. The position peaked at $2.56M in Q1 2020. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

  • Aurora Private Wealth reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
  • Aurora Private Wealth sold 3,513 Bristol-Myers Squibb shares in Q4 2023, an estimated $204K.
  • Aurora Private Wealth first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 16 quarters.
  • Aurora Private Wealth's Bristol-Myers Squibb position peaked at $2.56M in Q1 2020.
  • 2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Aurora Private Wealth's 13F filing for Q4 2023, filed 30 Jan 2024.